Per Kogner

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3450192/publications.pdf

Version: 2024-02-01

90 papers	4,048 citations	109321 35 h-index	123424 61 g-index
91 all docs	91 docs citations	91 times ranked	4782 citing authors

#	Article	IF	Citations
1	Sustained Response to Entrectinib in an Infant With a Germline ALKAL2 Variant and Refractory Metastatic Neuroblastoma With Chromosomal 2p Gain and Anaplastic Lymphoma Kinase and Tropomyosin Receptor Kinase Activation. JCO Precision Oncology, 2022, 6, e2100271.	3.0	8
2	Omega-3 fatty acids decrease CRYAB, production of oncogenic prostaglandin E2 and suppress tumor growth in medulloblastoma. Life Sciences, 2022, 295, 120394.	4.3	5
3	TC-hunter: identification of the insertion site of a transgenic gene within the host genome. BMC Genomics, 2022, 23, 149.	2.8	0
4	Filamin A increases aggressiveness of human neuroblastoma. Neuro-Oncology Advances, 2022, 4, vdac028.	0.7	1
5	The immune cell atlas of human neuroblastoma. Cell Reports Medicine, 2022, 3, 100657.	6.5	17
6	Aberrant splicing in neuroblastoma generates RNA-fusion transcripts and provides vulnerability to spliceosome inhibitors. Nucleic Acids Research, 2021, 49, 2509-2521.	14.5	12
7	Single-cell transcriptomics of human embryos identifies multiple sympathoblast lineages with potential implications for neuroblastoma origin. Nature Genetics, 2021, 53, 694-706.	21.4	90
8	Frequency and Prognostic Impact of ALK Amplifications and Mutations in the European Neuroblastoma Study Group (SIOPEN) High-Risk Neuroblastoma Trial (HR-NBL1). Journal of Clinical Oncology, 2021, 39, 3377-3390.	1.6	30
9	Body surface area-based omega-3 fatty acids supplementation strongly correlates to blood concentrations in children.. Prostaglandins Leukotrienes and Essential Fatty Acids, 2021, 169, 102285.	2.2	3
10	Single-nuclei transcriptomes from human adrenal gland reveal distinct cellular identities of low and high-risk neuroblastoma tumors. Nature Communications, 2021, 12, 5309.	12.8	38
11	Subcellular Distribution of p53 by the p53-Responsive lncRNA NBAT1 Determines Chemotherapeutic Response in Neuroblastoma. Cancer Research, 2021, 81, 1457-1471.	0.9	22
12	High Expression of PPM1D Induces Tumors Phenotypically Similar to TP53 Loss-of-Function Mutations in Mice. Cancers, 2021, 13, 5493.	3.7	6
13	PPM1D Is a Therapeutic Target in Childhood Neural Tumors. Cancers, 2021, 13, 6042.	3.7	5
14	Analysis of ALK, MYCN, and the ALK ligand ALKAL2 (FAM150B/AUGÎ±) in neuroblastoma patient samples with chromosome arm 2p rearrangements. Genes Chromosomes and Cancer, 2020, 59, 50-57.	2.8	18
15	Integrative discovery of treatments for high-risk neuroblastoma. Nature Communications, 2020, 11, 71.	12.8	42
16	11q Deletion or ALK Activity Curbs DLG2 Expression to Maintain an Undifferentiated State in Neuroblastoma. Cell Reports, 2020, 32, 108171.	6.4	25
17	Age Dependency of the Prognostic Impact of Tumor Genomics in Localized Resectable MYCN-Nonamplified Neuroblastomas. Report From the SIOPEN Biology Group on the LNESG Trials and a COG Validation Group. Journal of Clinical Oncology, 2020, 38, 3685-3697.	1.6	9
18	Establishment of an in vitro 3D model for neuroblastoma enables preclinical investigation of combined tumorâ€stroma drug targeting. FASEB Journal, 2020, 34, 11101-11114.	0.5	18

#	Article	IF	Citations
19	Whole-body MRI within a surveillance program for carriers with clinically actionable germline TP53 variants - the Swedish constitutional TP53 study SWEP53. Hereditary Cancer in Clinical Practice, 2020, 18, 1.	1.5	5
20	Low Frequency ALK Hotspots Mutations In Neuroblastoma Tumours Detected By Ultra-deep Sequencing: Implications For ALK Inhibitor Treatment. Scientific Reports, 2019, 9, 2199.	3.3	14
21	Sense-Antisense lncRNA Pair Encoded by Locus 6p22.3 Determines Neuroblastoma Susceptibility via the USP36-CHD7-SOX9 Regulatory Axis. Cancer Cell, 2018, 33, 417-434.e7.	16.8	122
22	Inhibition of Microsomal Prostaglandin E Synthase-1 in Cancer-Associated Fibroblasts Suppresses Neuroblastoma Tumor Growth. EBioMedicine, 2018, 32, 84-92.	6.1	60
23	Risk stratification of highâ€risk metastatic neuroblastoma: A report from the HRâ€NBLâ€1/SIOPEN study. Pediatric Blood and Cancer, 2018, 65, e27363.	1.5	53
24	Chromogranin A and neuron-specific enolase in neuroblastoma: Correlation to stage and prognostic factors. Pediatric Hematology and Oncology, 2018, 35, 156-165.	0.8	17
25	Clinical response of the novel activating ALK-I1171T mutation in neuroblastoma to the ALK inhibitor ceritinib. Journal of Physical Education and Sports Management, 2018, 4, a002550.	1.2	47
26	Targeting SAMHD1 with the Vpx protein to improve cytarabine therapy for hematological malignancies. Nature Medicine, 2017, 23, 256-263.	30.7	102
27	Busulfan and melphalan versus carboplatin, etoposide, and melphalan as high-dose chemotherapy for high-risk neuroblastoma (HR-NBL1/SIOPEN): an international, randomised, multi-arm, open-label, phase 3 trial. Lancet Oncology, The, 2017, 18, 500-514.	10.7	256
28	Accelerating drug development for neuroblastoma - New Drug Development Strategy: an Innovative Therapies for Children with Cancer, European Network for Cancer Research in Children and Adolescents and International Society of Paediatric Oncology Europe Neuroblastoma project. Expert Opinion on Drug Discovery, 2017, 12, 1-11.	5.0	28
29	Rho-associated kinase is a therapeutic target in neuroblastoma. Proceedings of the National Academy of Sciences of the United States of America, 2017, 114, E6603-E6612.	7.1	52
30	Improved Local Control by Extensive Surgery in High-Risk Neuroblastoma May Be Dependent on Adjuvant Radiotherapy. Journal of Clinical Oncology, 2017, 35, 1965-1966.	1.6	7
31	Venetoclax in cancer therapy and potential effects on bone. Lancet Oncology, The, 2016, 17, e319-e320.	10.7	0
32	Regulation of myeloid cells by activated T cells determines the efficacy of PD-1 blockade. OncoImmunology, 2016, 5, e1232222.	4.6	48
33	Regulation of Nuclear Hormone Receptors by MYCN-Driven miRNAs Impacts Neural Differentiation and Survival in Neuroblastoma Patients. Cell Reports, 2016, 16, 979-993.	6.4	19
34	Planar cell polarity gene expression correlates with tumor cell viability and prognostic outcome in neuroblastoma. BMC Cancer, 2016, 16, 259.	2.6	20
35	Genome-wide methylation profiling identifies novel methylated genes in neuroblastoma tumors. Epigenetics, 2016, 11, 74-84.	2.7	63
36	Estimation of copy number aberrations: Comparison of exome sequencing data with SNP microarrays identifies homozygous deletions of 19q13.2 and CIC in neuroblastoma. International Journal of Oncology, 2016, 48, 1103-1116.	3.3	18

#	Article	IF	Citations
37	Targeting Suppressive Myeloid Cells Potentiates Checkpoint Inhibitors to Control Spontaneous Neuroblastoma. Clinical Cancer Research, 2016, 22, 3849-3859.	7.0	109
38	Prognostic factors in stage 4 neuroblastoma treated with busulphan-melphalan: Report from the European HR-NBL1/Siopen trial.. Journal of Clinical Oncology, 2016, 34, 10527-10527.	1.6	1
39	COX/mPGES-1/PGE ₂ pathway depicts an inflammatory-dependent high-risk neuroblastoma subset. Proceedings of the National Academy of Sciences of the United States of America, 2015, 112, 8070-8075.	7.1	88
40	Intragenic anaplastic lymphoma kinase (ALK) rearrangements: Translocations as a novel mechanism of ALK activation in neuroblastoma tumors. Genes Chromosomes and Cancer, 2015, 54, 99-109.	2.8	45
41	Emergence of New ALK Mutations at Relapse of Neuroblastoma. Journal of Clinical Oncology, 2014, 32, 2727-2734.	1.6	176
42	Immunotherapy (IT) with ch14.18/CHO for high-risk neuroblastoma: First results from the randomised HR-NBL1/SIOPEN trial.. Journal of Clinical Oncology, 2014, 32, 10026-10026.	1.6	3
43	Emergence of new ALK mutations at relapse of neuroblastoma.. Journal of Clinical Oncology, 2014, 32, 11006-11006.	1.6	0
44	Dual Targeting of Wild-Type and Mutant p53 by Small Molecule RITA Results in the Inhibition of N-Myc and Key Survival Oncogenes and Kills Neuroblastoma Cells In Vivo and In Vitro. Clinical Cancer Research, 2013, 19, 5092-5103.	7.0	55
45	Cell culture andDrosophilamodel systems define three classes of anaplastic lymphoma kinase mutations in neuroblastoma. DMM Disease Models and Mechanisms, 2013, 6, 373-82.	2.4	59
46	Low-dose aspirin delays an inflammatory tumor progression in vivo in a transgenic mouse model of neuroblastoma. Carcinogenesis, 2013, 34, 1081-1088.	2.8	60
47	The microenvironment of human neuroblastoma supports the activation of tumor-associated T lymphocytes. OncoImmunology, 2013, 2, e23618.	4.6	32
48	Neuroblastoma-related inflammation. OncoImmunology, 2013, 2, e24658.	4.6	14
49	Tumor Development, Growth Characteristics and Spectrum of Genetic Aberrations in the TH-MYCN Mouse Model of Neuroblastoma. PLoS ONE, 2012, 7, e51297.	2.5	43
50	Comprehensive SNP array study of frequently used neuroblastoma cell lines; copy neutral loss of heterozygosity is common in the cell lines but uncommon in primary tumors. BMC Genomics, 2011, 12, 443.	2.8	33
51	Appearance of the Novel Activating F1174S ALK Mutation in Neuroblastoma Correlates with Aggressive Tumor Progression and Unresponsiveness to Therapy. Cancer Research, 2011, 71, 98-105.	0.9	80
52	High-risk neuroblastoma tumors with 11q-deletion display a poor prognostic, chromosome instability phenotype with later onset. Proceedings of the National Academy of Sciences of the United States of America, 2010, 107, 4323-4328.	7.1	200
53	Randomized Trial of Prophylactic Granulocyte Colony-Stimulating Factor During Rapid COJEC Induction in Pediatric Patients With High-Risk Neuroblastoma: The European HR-NBL1/SIOPEN Study. Journal of Clinical Oncology, 2010, 28, 3516-3524.	1.6	114
54	Meta-analysis of Neuroblastomas Reveals a Skewed ALK Mutation Spectrum in Tumors with MYCN Amplification. Clinical Cancer Research, 2010, 16, 4353-4362.	7.0	243

#	Article	IF	Citations
55	Embryonal neural tumours and cell death. Apoptosis: an International Journal on Programmed Cell Death, 2009, 14, 424-438.	4.9	57
56	Soluble factors released by activated cytotoxic T lymphocytes interfere with death receptor pathways in neuroblastoma. Cancer Immunology, Immunotherapy, 2008, 57, 731-743.	4.2	6
57	Assessment of NORE1A as a putative tumor suppressor in human neuroblastoma. International Journal of Cancer, 2008, 123, 389-394.	5.1	18
58	High-resolution array copy number analyses for detection of deletion, gain, amplification and copy-neutral LOH in primary neuroblastoma tumors: Four cases of homozygous deletions of the CDKN2A gene. BMC Genomics, 2008, 9, 353.	2.8	84
59	High incidence of DNA mutations and gene amplifications of the ALK gene in advanced sporadic neuroblastoma tumours. Biochemical Journal, 2008, 416, 153-159.	3.7	246
60	Celecoxib Prevents Neuroblastoma Tumor Development and Potentiates the Effect of Chemotherapeutic Drugs In vitro and In vivo. Clinical Cancer Research, 2007, 13, 1036-1044.	7.0	56
61	Cyclooxygenase-2 Is Expressed in Neuroblastoma, and Nonsteroidal Anti-Inflammatory Drugs Induce Apoptosis and Inhibit Tumor Growth In vivo. Cancer Research, 2004, 64, 7210-7215.	0.9	105
62	The vitamin A analogues: 13-cis retinoic acid, 9-cis retinoic acid, and Ro 13-6307 inhibit neuroblastoma tumour growth in vivo. Medical and Pediatric Oncology, 2001, 36, 127-131.	1.0	27
63	Absence of somatostatin receptor expression in vivo is correlated to di- or tetraploid 1p36-deleted neuroblastomas. Medical and Pediatric Oncology, 2001, 36, 56-60.	1.0	5
64	Fine mapping of a tumour suppressor candidate gene region in 1p36.2-3, commonly deleted in neuroblastomas and germ cell tumours. Medical and Pediatric Oncology, 2001, 36, 61-66.	1.0	31
65	RASSF1A promoter region CpG island hypermethylation in phaeochromocytomas and neuroblastoma tumours. Oncogene, 2001, 20, 7573-7577.	5.9	127
66	Combined111In-pentetreotide scintigraphy and123I-mIBG scintigraphy in neuroblastoma provides prognostic information. Medical and Pediatric Oncology, 2000, 35, 688-691.	1.0	48
67	Gain of chromosome arm 17q is associated with unfavourable prognosis in neuroblastoma, but does not involve mutations in the somatostatin receptor 2 (SSTR2) gene at 17q24. British Journal of Cancer, 1999, 81, 1402-1409.	6.4	46
68	The use of fine-needle aspiration cytology in the molecular characterization of neuroblastoma in children. Cancer, 1999, 87, 60-68.	4.1	37
69	The use of fineâ€needle aspiration cytology in the molecular characterization of neuroblastoma in children. Cancer, 1999, 87, 60-68.	4.1	2
70	The Somatostatin Analogue Octreotide Inhibits Neuroblastoma Growth in Vivo. Pediatric Research, 1999, 46, 328-332.	2.3	18
71	Promoter-specific methylation and expression alterations of igf2 and h19 are involved in human hepatoblastoma. , 1998, 75, 176-180.		24
72	What can we expect from neuroblastoma screening? Clinicians point of view. Medical and Pediatric Oncology, 1998, 31, 408-418.	1.0	5

#	Article	IF	Citations
73	Screening for neuroblastoma: ethical and psychological aspects. Medical and Pediatric Oncology, 1998, 31, 421-425.	1.0	3
74	Somatostatin in neuroblastoma and ganglioneuroma. European Journal of Cancer, 1997, 33, 2084-2089.	2.8	41
75	Delimitation of a critical tumour suppressor region at distal 1p in neuroblastoma tumours. European Journal of Cancer, 1997, 33, 1997-2001.	2.8	49
76	Monosomy 1p36.31â€“33â†’pter due to a paternal reciprocal translocation: Prognostic significance of FISH analysis. , 1996, 65, 60-67.		22
77	Chapter 18 Neuropeptides in neuroblastomas and ganglioneuromas. Progress in Brain Research, 1995, 104, 325-338.	1.4	18
78	Pancreastatin immunoreactivity in favourable childhood neuroblastoma and ganglioneuroma. European Journal of Cancer, 1995, 31, 557-560.	2.8	14
79	Plasma neuropeptide Y in healthy children: influence of age, anaesthesia and the establishment of an ageâ€adjusted reference interval. Acta Paediatrica, International Journal of Paediatrics, 1994, 83, 423-727.	1.5	27
80	Expression of nerve growth factor receptor mRNAs and clinical response to retinoic acid in neuroblastoma. Progress in Clinical and Biological Research, 1994, 385, 147-53.	0.2	7
81	Neuropeptide Y in neuroblastoma: Increased concentration in metastasis, release during surgery, and characterization of plasma and tumor extracts. Medical and Pediatric Oncology, 1993, 21, 317-322.	1.0	30
82	Coexpression of messenger RNA for TRK protooncogene and low affinity nerve growth factor receptor in neuroblastoma with favorable prognosis. Cancer Research, 1993, 53, 2044-50.	0.9	165
83	Neuropeptide Y (NPY) synthesis in lymphoblasts and increased plasma NPY in pediatric B-cell precursor leukemia. Blood, 1992, 80, 1324-1329.	1.4	27
84	N-myc Gene Amplification in Neuroblastoma: A Clinical Approach Using Ultrasound Guided Cutting Needle Biopsies Collected at Diagnosis. Medical and Pediatric Oncology, 1992, 20, 292-300.	1.0	29
85	Neuropeptide Y (NPY) synthesis in lymphoblasts and increased plasma NPY in pediatric B-cell precursor leukemia. Blood, 1992, 80, 1324-1329.	1.4	0
86	Neuropeptide Y (NPY) synthesis in lymphoblasts and increased plasma NPY in pediatric B-cell precursor leukemia. Blood, 1992, 80, 1324-9.	1.4	5
87	Characterization of neuropeptide Y in pediatric neural crest tumors: relation to tumor malignancy and genetic findings. Progress in Clinical and Biological Research, 1991, 366, 351-7.	0.2	0
88	Plasma neuropeptide Y (NPY): a novel marker of neuroblastoma. Progress in Clinical and Biological Research, 1991, 366, 367-73.	0.2	3
89	Neuropeptide Y as a Marker in Pediatric Neuroblastoma. Pediatric Pathology, 1990, 10, 207-216.	0.5	21
90	11q Deletion or ALK Activity Curbs DLG2 Expression to Maintain an Undifferentiated State in Neuroblastoma. SSRN Electronic Journal, 0, , .	0.4	0